Global Hemophilia Treatment Drugs Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hemophilia Treatment Drugs Sales Market Report 2024
Market Analysis and InsightsGlobal Hemophilia Treatment Drugs Market
Hemophilia is a rare disorder in which your blood doesn't clot normally because it lacks sufficient blood-clotting proteins (clotting factors).
Due to the COVID-19 pandemic, the global Hemophilia Treatment Drugs market size is estimated to be worth US$ 10830 million in 2024 and is forecast to a readjusted size of US$ 14190 million by 2034 with a CAGR of 3.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Recombinant Coagulation Factor Concentrates accounting for % of the Hemophilia Treatment Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
The United States Hemophilia Treatment Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Hemophilia Treatment Drugs include Pfizer, Biotest, CSL Behring, Kedrion, Octapharma, Takeda, Novo Nordisk, Bayer and Roche, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Hemophilia Treatment Drugs Scope and Market Size
The global Hemophilia Treatment Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Hemophilia Treatment Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Recombinant Coagulation Factor Concentrates
Plasma Derived Coagulation Factor Concentrates
Desmopressin
Antifibrinolytic Agents
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Pfizer
Biotest
CSL Behring
Kedrion
Octapharma
Takeda
Novo Nordisk
Bayer
Roche
Biogen
Hemophilia is a rare disorder in which your blood doesn't clot normally because it lacks sufficient blood-clotting proteins (clotting factors).
Due to the COVID-19 pandemic, the global Hemophilia Treatment Drugs market size is estimated to be worth US$ 10830 million in 2024 and is forecast to a readjusted size of US$ 14190 million by 2034 with a CAGR of 3.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Recombinant Coagulation Factor Concentrates accounting for % of the Hemophilia Treatment Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
The United States Hemophilia Treatment Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Hemophilia Treatment Drugs include Pfizer, Biotest, CSL Behring, Kedrion, Octapharma, Takeda, Novo Nordisk, Bayer and Roche, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Hemophilia Treatment Drugs Scope and Market Size
The global Hemophilia Treatment Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Hemophilia Treatment Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Recombinant Coagulation Factor Concentrates
Plasma Derived Coagulation Factor Concentrates
Desmopressin
Antifibrinolytic Agents
Segment by Application
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Pfizer
Biotest
CSL Behring
Kedrion
Octapharma
Takeda
Novo Nordisk
Bayer
Roche
Biogen
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices